RxDoctor Payments Data

William McManus, MD

Interventional Cardiology · Stuart, FLNPI 1265517619

Payments from drug & device makers

$8,175in general payments, 2019–2025

Across 498 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$994
  • Johnson & Johnson$937
  • E.r. Squibb & Sons, L.L.C.$936
  • Novartis$704
  • Pfizer$627
  • Sanofi-aventis U.S. LLC$366
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$92511%
  • Food & beverage$7,21688%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,175 in reported general payments places this provider in the 45th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$1,637,740
Medicare patients
2,803
Services billed
13,548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban810$995,167
XareltoRivaroxaban219$238,732
EntrestoSacubitril/Valsartan149$198,597
Repatha SureclickEvolocumab121$132,624
MultaqDronedarone Hcl33$54,408
Praluent PenAlirocumab31$35,129
BrilintaTicagrelor19$17,419
VascepaIcosapent Ethyl13$13,256
Metoprolol Succinate873$12,256
Rosuvastatin Calcium894$11,980
DiovanValsartan13$9,214
Losartan Potassium632$6,361
Atorvastatin Calcium585$6,084
Dabigatran EtexilateDabigatran Etexilate Mesylate18$4,981
Dofetilide16$4,841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$627$995,167810 claims
Johnson & JohnsonXarelto$937$238,732219 claims
NovartisEntresto, Diovan$704$207,812162 claims
Sanofi-aventis U.S. LLCMultaq$366$54,40833 claims
AstraZenecaBrilinta$295$17,41919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →